It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Amy Schumer’s experience with Mounjaro has been vastly different from when she tried an alternative weight-loss medication ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...

Mounjaro, a newly launched weight-loss and diabetes drug, is now available in India. Developed by Eli Lilly, it promises more effectiveness than Ozempic and comes at a lower cost. Experts believe it ...

Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

Antiobesity medications tirzepatide and semaglutide offer long-term health benefits but are not cost-effective.

Viking Therapeutics shares rocketed to an all-time high last February after the company announced positive clinical trial results for its weight-management candidate, VK2735. This is a dual GLP-1 and ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

A vegan diet rich in low-fat plant-based foods can lead to significant weight loss, regardless ... who persisted with Tirzepatide for at least six months lost an average of 12.9% of their body ...